Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 4/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL7302779 | 0.84 | CFTR (0.59) | CFTRKMT2ASMN1; SMN2MEN1USP2 | |
| SCHEMBL4591354 | 0.84 | CFTR (0.59) | CFTRKMT2ASMN1; SMN2MEN1USP2 | |
| SCHEMBL4590994 | 0.84 | HSD17B10 (0.48) | CFTRKDM4EUSP2TSHRHSD17B10 | |
| SCHEMBL4590900 | 0.82 | KDM4E (0.55) | CFTRKMT2AKDM4EUSP2TSHR | |
| SCHEMBL7291065 | 0.81 | ROCK1 (0.46) | CFTRKDM4EUSP2TSHRHSD17B10 | |
| SCHEMBL7293503 | 0.79 | PRKCD (0.48) | CFTRKDM4EUSP2TSHRHSD17B10 | |
| SCHEMBL7292623 | 0.78 | PRKCD (0.44) | CFTRKDM4EUSP2TSHRHSD17B10 | |
| SCHEMBL4590902 | 0.78 | CFTR (0.40) | CFTRSMN1; SMN2KDM4EUSP2TSHR | |
| SCHEMBL7292620 | 0.76 | KDM4E (0.50) | KMT2AMEN1KDM4EUSP2TSHR | |
| SCHEMBL7284439 | 0.76 | PRKCH (0.46) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1741709-A1 | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | claimed |
| US-8518976-B2 | e.g. 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)-1H-pyridin-2-one; endothelial nitric oxide NO synthase inhibitor; antiinflammatory, hypotensive agent; atherosclerosis, thrombosis, coronary artery disease, and cardiac insufficiency | SANOFI (FR) | 2013-08-27 | — | — | US | disclosed |
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-17 | — | — | US | disclosed |
| EP-1899321-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| EP-1741709-A1 | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2007000246-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | TBXAS1, PTGIS, NOS2 | CFTR 1636/4885MAOB 187/4885KMT2A 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.